Cancer NetworkOriginal article
<![CDATA[MELT-MM Regimen Yields Responses in Relapsed/Refractory Multiple Myeloma]]>
Phase 1positiveelranatamabmezigdomidePositive
AI Analysis
Summary
The MELT-MM phase 1b trial demonstrated a 100% overall response rate for the combination of elranatamab and mezigdomide in relapsed/refractory multiple myeloma patients. This positive early-stage data suggests potential clinical benefit for this combination approach.
Clinical Trial Data
Phase
1b
Primary Endpoint
Met
Outcome Details
100% overall response rate in phase 1b portion of MELT-MM trial
Importance:6/10
Sentiment:
0.85
multiple myelomaoncologycombination therapyclinical trialhigh response rate
Read the original article
Published by Cancer Network on September 24, 2026 7:00 PM